×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADMA – adma biologics inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADMA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
10:45 am
adma
The Schall Law Firm Encourages Shareholders To Take Part In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholders To Take Part In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/20
07:50 pm
adma
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
11/20
12:00 pm
adma
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
Low
Report
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
11/19
12:00 pm
adma
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/18
09:12 pm
adma
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
11/18
12:45 pm
adma
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm
Low
Report
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm
11/17
12:00 pm
adma
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Low
Report
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/16
12:00 pm
adma
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:31 pm
adma
Form 8-K ADMA BIOLOGICS, INC. For: Nov 19
Low
Report
Form 8-K ADMA BIOLOGICS, INC. For: Nov 19
11/12
01:35 pm
adma
Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
11/8
09:23 am
adma
Form SC 13G ADMA BIOLOGICS, INC. Filed by: Invesco Ltd.
Medium
Report
Form SC 13G ADMA BIOLOGICS, INC. Filed by: Invesco Ltd.
11/7
05:04 pm
adma
Form 10-Q ADMA BIOLOGICS, INC. For: Sep 30
Medium
Report
Form 10-Q ADMA BIOLOGICS, INC. For: Sep 30
11/7
04:13 pm
adma
Form 8-K ADMA BIOLOGICS, INC. For: Nov 07
Medium
Report
Form 8-K ADMA BIOLOGICS, INC. For: Nov 07
11/4
11:01 am
adma
Form SC 13G ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
10/31
05:26 pm
adma
Form 8-K ADMA BIOLOGICS, INC. For: Oct 31
High
Report
Form 8-K ADMA BIOLOGICS, INC. For: Oct 31
10/17
09:23 am
adma
Form SC 13G ADMA BIOLOGICS, INC. Filed by: STATE STREET CORP
Low
Report
Form SC 13G ADMA BIOLOGICS, INC. Filed by: STATE STREET CORP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/20
Form 8-K ADMA BIOLOGICS, INC. For: Mar 20
36.6%
1/9 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook 17.6%
3/3 Form 4 ADMA BIOLOGICS, INC. For: Feb 28 Filed by: Grossman Adam S 10.8%
3/10 Form SEC STAFF LETTER ADMA BIOLOGICS, INC. 8.6%
5/21 ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 8.5%
8/23 Form 8-K ADMA BIOLOGICS, INC. For: Aug 23 7.7%
9/5 Form 8-K ADMA BIOLOGICS, INC. For: Aug 29 7.3%
5/8 Q1/2019 3/31/2019 EPS -0.280 ZacksConsensus -0.320 ActVsEst 0.040 - Beat 7.3%
7/8 Form 8-K ADMA BIOLOGICS, INC. For: Jul 02 6.9%
10/21 ADMA Biologics Announces First Commercial Sales of ASCENIV™ 6.5%
1/9 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook 17.6%
3/3 Form 4 ADMA BIOLOGICS, INC. For: Feb 28 Filed by: Grossman Adam S 10.8%
3/10 Form SEC STAFF LETTER ADMA BIOLOGICS, INC. 8.6%
5/21 ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 8.5%
8/23 Form 8-K ADMA BIOLOGICS, INC. For: Aug 23 7.7%
9/5 Form 8-K ADMA BIOLOGICS, INC. For: Aug 29 7.3%
5/8 Q1/2019 3/31/2019 EPS -0.280 ZacksConsensus -0.320 ActVsEst 0.040 - Beat 7.3%
7/8 Form 8-K ADMA BIOLOGICS, INC. For: Jul 02 6.9%
10/21 ADMA Biologics Announces First Commercial Sales of ASCENIV™ 6.5%
TOP News Decliners
2/6
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
-14.3%
6/6 Form 8-K ADMA BIOLOGICS, INC. For: Jun 06 -12.3%
10/2 Form 8-K ADMA BIOLOGICS, INC. For: Oct 02 -11.2%
11/6 Form 8-K ADMA BIOLOGICS, INC. For: Nov 06 -10.5%
3/5 ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -10.4%
3/3 New U.S. patent lifts Adma Biologics, up 17% premarket [Seeking Alpha] -9.9%
3/16 ADMA Biologics Inc (NASDAQ: ADMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $14.00. -9.1%
10/3 Form 8-K ADMA BIOLOGICS, INC. For: Oct 03 -8.5%
3/9 Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: BlackRock Inc. -7.5%
12/3 ADMA Biologics Inc (NASDAQ: ADMA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.0%
6/6 Form 8-K ADMA BIOLOGICS, INC. For: Jun 06 -12.3%
10/2 Form 8-K ADMA BIOLOGICS, INC. For: Oct 02 -11.2%
11/6 Form 8-K ADMA BIOLOGICS, INC. For: Nov 06 -10.5%
3/5 ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -10.4%
3/3 New U.S. patent lifts Adma Biologics, up 17% premarket [Seeking Alpha] -9.9%
3/16 ADMA Biologics Inc (NASDAQ: ADMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $14.00. -9.1%
10/3 Form 8-K ADMA BIOLOGICS, INC. For: Oct 03 -8.5%
3/9 Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: BlackRock Inc. -7.5%
12/3 ADMA Biologics Inc (NASDAQ: ADMA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: